All articles by Swagath Bandhakavi

Swagath Bandhakavi

CSL Behring’s Hemgenix administered to first haemophilia B patients in Europe

Last year, the European Commission granted conditional marketing authorisation for Hemgenix to treat severe and moderately severe haemophilia B in adults without a history of Factor IX inhibitors

Ascentage Pharma announces closing of $75m equity investment by Takeda

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death

C-Path and Centogene partner to advance drug development for lysosomal diseases

The partnership aims to leverage the strengths of both organisations in genetic and real-world data to address challenges in developing safe and effective treatments for LDs

Gilead’s lenacapavir meets key efficacy endpoints of superiority in Phase 3 HIV trial

According to topline results from an interim analysis, the twice-yearly injectable HIV-1 capsid inhibitor achieved 100% efficacy in its investigational use

Dizal gains Chinese approval for golidocitinib in relapsed or refractory PTCL

The NMPA approval was driven by the findings of the JACKPOT8 Part B study in which golidocitinib monotherapy demonstrated superior and durable antitumour efficacy compared to existing treatment options

GenFleet receives IND approval from China’s NMPA for GFH375

G12D mutation is the most prevalent KRAS mutation detected in human cancers, and no G12D-targeted therapies have been approved yet

Aurion Biotech’s AURN001 gets BTD and RMAT designations from FDA

Its breakthrough therapy and regenerative medicine advanced therapy designations follow the completion of enrolment and dosing in the CLARA Phase 1/2 clinical trial across sites in the US and Canada